Drug · CHEMBL40
PHENOBARBITAL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PHENOBARBITAL. Drugs and targets, record CHEMBL40. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL40
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases13
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 13Source Open Targets
See all 13 diseasesTrials30
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01720667 | Efficacy of Intravenous Levetiracetam in Neonatal Seizures | Phase 1/2 | 280 | 2019-08-21 | phenobarbital | Its name | ClinicalTrials.gov |
| NCT01184417 | Phenobarbital for Acute Alcohol Withdrawal | 102 | 2012-03-09 | phenobarbital | Its name | ClinicalTrials.gov | |
| NCT01175668 | Clonidine for Neonatal Abstinence Syndrome Study | 68 | 2014-01-06 | phenobarbital | Its name | ClinicalTrials.gov | |
| NCT01982812 | A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM | Phase 2 | 44 | 2016-07-29 | phenobarbital | Its name | ClinicalTrials.gov |
| NCT01723722 | Treatment of Neonatal Abstinence Syndrome | Phase 4 | 40 | 2013-11-27 | phenobarbital | Its name | ClinicalTrials.gov |
| NCT03670160 | Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome | Phase 2 | 25 | 2021-11-09 | phenobarbital | Its name | ClinicalTrials.gov |
| NCT01089504 | Prophylactic Phenobarbital After Neonatal Seizures | Phase 4 | 13 | 2016-02-03 | phenobarbital | Its name | ClinicalTrials.gov |
| NCT00009620 | Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage | Phase 3 | 610 | phenobarbital | Its name | ClinicalTrials.gov | |
| NCT02374567 | Pharmacovigilance in Gerontopsychiatric Patients | Phase 3 | 407 | phenobarbital | Its name | ClinicalTrials.gov | |
| NCT01284556 | Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures | Phase 3 | 314 | phenobarbital | Its name | ClinicalTrials.gov |
1 to 10 of 30
See all 30 trialsComparisons in its trials21
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Intravenous Phenobarbital vs Intravenous Levetiracetam: deaths from any cause | 1 of 42 | 2 of 64 | 106 | NCT01720667 | Trial comparisons |
| Intravenous Phenobarbital vs Intravenous Levetiracetam: serious adverse events | 5 of 42 | 1 of 64 | 106 | NCT01720667 | Trial comparisons |
| Phenobarbital Group vs Placebo Group: Number of Patients Requiring Continuous Lorazepam Infusion | 2 of 51 | 16 of 51 | 102 | NCT01184417 | Trial comparisons |
| Phenobarbital Group vs Placebo Group: Number of Study Patients With Seizure as a Measure of Safety and Tolerability | 1 of 51 | 2 of 51 | 102 | NCT01184417 | Trial comparisons |
| Phenobarbital Group vs Placebo Group: Number of Patients Requiring Endotracheal Intubation as a Measure of Safety and Tolerability | 0 of 51 | 0 of 51 | 102 | NCT01184417 | Trial comparisons |
| Phenobarbital Group vs Placebo Group: Number of Study Patients With Mortality as a Measure of Safety and Tolerability | 0 of 51 | 0 of 51 | 102 | NCT01184417 | Trial comparisons |
| Phenobarbital Group vs Placebo Group: serious adverse events | 0 of 51 | 0 of 51 | 102 | NCT01184417 | Trial comparisons |
| Intravenous Levetiracetam vs Intravenous Phenobarbital: Number of Neonates With Seizure Termination at 1 Hour After Treatment | 26 of 53 | 28 of 30 | 83 | NCT01720667 | Trial comparisons |
| Intravenous Levetiracetam vs Intravenous Phenobarbital: Neonates With Seizure Cessation When Given Levetiracetam (40-60 mg/kg) as First Line Therapy Compared to Phenobarbital (20-40mg/kg) | 15 of 53 | 24 of 30 | 83 | NCT01720667 | Trial comparisons |
| Intravenous Levetiracetam vs Intravenous Phenobarbital: LEV Dose Escalation Component | 4 of 53 | 3 of 30 | 83 | NCT01720667 | Trial comparisons |
1 to 10 of 21
See all 21 comparisons in its trialsPapers from its trials23
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL40
GET https://conductscience.org/api/drugs/v1/CHEMBL40/trials?page=2